-

MONTAUK RENEWABLES, INC. INVESTIGATION: MNTK Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Montauk Renewables, Inc. (“Montauk” or the “Company”) (NASDAQ: MNTK). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. If you purchased or otherwise acquired Montauk securities, please contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to learn more about your rights.

[LEARN MORE ABOUT POTENTIAL SECURITIES FRAUD CLAIMS]

What Happened?

On November 10, 2026, Montauk filed a Notification of Late Filing on Form NT 10-Q with the SEC, stating that the Company is unable to timely file its Quarterly Report on Form 10-Q “as a result of ongoing negotiations with the lender under the Company’s New Senior Credit Facility Agreement (‘New Senior Credit Facility’).” Montauk stated, “In October 2026, the Company experienced difficulty in meeting certain engineering review and operational requirements in placing its Turkey, North Carolina facility in service, which has impacted its ability to draw down additional debt under its New Senior Credit Facility.” The Company explained that it is trying to renegotiate the terms of the New Senior Credit Facility to obtain “an amendment to borrow additional debt and temporarily forbear and standstill certain debt covenant requirements,” but there “can be no assurance that the Company will be successful in obtaining relief… or raising any additional financing.” On this news, the price of Montauk shares declined by $1.59 per share, or approximately 57.2%, from $2.78 per share on November 9, 2026 to close at $1.19 on November 10, 2026.

What Should I Do?

At this stage, no lawsuit has been filed. The investigation is ongoing to determine whether claims may be brought under federal securities laws.

If you purchased or otherwise acquired Montauk securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.

[LEARN MORE ABOUT YOUR RIGHTS AS AN INVESTOR]

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found on Kirby McInerney LLP’s website.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Kirby McInerney LLP

NASDAQ:MNTK

Release Versions
$Cashtags

Contacts

More News From Kirby McInerney LLP

GILAT SATELLITE NETWORKS LTD. INVESTIGATION: GILT Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Gilat Satellite Networks Ltd. (“Gilat” or the “Company”) (NASDAQ: GILT). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. If you purchased or otherwise acquired Gilat securities, please contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp....

BRIGHT MINDS BIOSCIENCES DRUG INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 52.3% Share Drop

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Bright Minds Biosciences (“Bright Minds” or the “Company”) (NASDAQ: DRUG) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.[LEARN MORE ABOUT THE FIRM’S INVESTIGATION]What Happened?On November 2, 2026, Bright Minds announced that the FDA had notified the Company that it...

MADRIGAL PHARMACEUTICALS, INC. MDGL INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 8.1% Share Drop

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Madrigal Pharmaceuticals, Inc. (“Madrigal” or the “Company”) (NASDAQ: MDGL) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.[LEARN MORE ABOUT THE FIRM’S INVESTIGATION]What Happened?On November 3, 2026, Madrigal disclosed in its quarterly report on Form 10-Q that, on Oc...
Back to Newsroom